Pamoic acid disodium salt
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Pamoic acid disodium salt, a supposedly inactive component in many formulations of drugs used to modulate release, is a potent agonist of the orphan receptor GPR35. GPR35 is a class A, rhodopsin-like G protein-coupled receptor (GPCR), strongly expressed in the lower intestine and colon, dorsal root ganglia, as well as a variety of immune cells including monocytes and dendritic cells. Targeting GPR35 provides potential therapeutic opportunities in a range of conditions, such as inflammation, pain and cancer.
References:
1. Zhao P, Sharir H, Kapur A, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Molecular Pharmacology, 2010, 78(4): 560-568.
2. Quon T, Lin LC, Ganguly A, et al. Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35. ACS Pharmacology & Translational Science, 2020, 3(5): 801-812.
| Physical Appearance | Pale yellow solid |
| Storage | Desiccate at RT |
| M.Wt | 432.33 |
| Cas No. | 6640-22-8 |
| Formula | C23H14Na2O6 |
| Solubility | insoluble in EtOH; ≥18 mg/mL in H2O; ≥28.6 mg/mL in DMSO |
| Chemical Name | sodium 1,1'-methylenebis(3-carboxynaphthalen-2-olate) |
| SDF | Download SDF |
| Canonical SMILES | [O-]C1=C(C2=CC=CC=C2C=C1C(O)=O)CC(C3=CC=CC=C3C=C4C(O)=O)=C4[O-].[Na+].[Na+] |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| Cell experiment:[1] | |
|
Cell lines |
U2OS cells expressing human GPR35a |
|
Reaction Conditions |
15 min incubation |
|
Applications |
Pamoic acid potently recruited β-arrestin2 to GPR35 (EC50 = 79 nM), dose-dependently increased ERK1/2 phosphorylation (1 ~ 10 μM, 30 min incubation), and induced GPR35 translocation from the plasma membrane to the cytoplasm (EC50 = 22 nM) in U20S cells expressing human GPR35a. |
| Animal experiment:[1] | |
|
Animal models |
Male Swiss-Webster mice, 30–35 g |
|
Dosage form |
25, 50 and 100 mg/kg Subcutaneous administration |
|
Applications |
Pamoic acid exhibited dose-related antinociception in a mouse model of visceral pain perception, with an ED50 value of 40.5 mg/kg. Complete antinociception could be achieved with 100 mg/kg pamoic acid. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Zhao P, Sharir H, Kapur A, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Molecular Pharmacology, 2010, 78(4): 560-568. 2. Quon T, Lin LC, Ganguly A, et al. Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35. ACS Pharmacology & Translational Science, 2020, 3(5): 801-812. |
|
质量控制和MSDS
- 批次:
化学结构
